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Leprosy is a spectral disease exhibiting two polar sides, namely, lepromatous leprosy (LL) characterised by 
impaired T-cell responses and tuberculoid leprosy in which T-cell responses are strong. Proper T-cell activation 
requires signalling through costimulatory molecules expressed by antigen presenting cells and their ligands on 
T-cells. We studied the influence of costimulatory molecules on the immune responses of subjects along the leprosy 
spectrum. The expression of the costimulatory molecules was evaluated in in vitro-stimulated peripheral blood 
mononuclear cells of lepromatous and tuberculoid patients and healthy exposed individuals (contacts). We show 
that LL patients have defective monocyte CD86 expression, which likely contributes to the impairment of the antigen 
presentation process and to patients anergy. Accordingly, CD86 but not CD80 blockade inhibited the lymphopro-
liferative response to Mycobacterium leprae. Consistent with the LL anergy, there was reduced expression of the 
positive signalling costimulatory molecules CD28 and CD86 on the T-cells in these patients. In contrast, tubercu-
loid leprosy patients displayed increased expression of the negative signalling molecules CD152 and programmed 
death-1 (PD-1), which represents a probable means of modulating an exacerbated immune response and avoiding 
immunopathology. Notably, the contacts exhibited proper CD86 and CD28 expression but not exacerbated CD152 
or PD-1 expression, suggesting that they tend to develop a balanced immunity without requiring immunosuppressive 
costimulatory signalling. 
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Although the prevalence of leprosy has been decreas-
ing all over the world, hyper-endemic areas persist where 
the transmission of leprosy is still out of control (WHO 
2010). Leprosy, caused by the bacillus Mycobacterium 
leprae, is a chronic, incapacitating disease that affects 
the peripheral nerves and skin. Leprosy manifests as a 
spectral disease. The lepromatous form of the disease, 
comprising both borderline lepromatous leprosy (BL) 
and lepromatous leprosy (LL), is a consequence of the 
impaired immune cellular response of the patient and is 
characterised by an antigen-specific anergy, a Th-2 pat-
tern of immune response and a lack of control of bacilli 
multiplication. The tuberculoid form of the disease, com-
prising both borderline tuberculoid (BT) and tuberculoid 
tuberculoid (TT) leprosy, corresponds to the more benign 
form of the disease and is characterised by a strong gran-
ulomatous response and the control of bacilli multiplica-
tion (Yamamura et al. 1991, Sinsimer et al. 2010). 
Thus, a protective immune response in leprosy is 
considered to rely on the cellular arm of the immune 
system, specifically on the generation of helper T-cells 
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that can activate cells from the monocytic lineage (mac-
rophages, dendritic cells and Schawnn cells, among oth-
ers) to destroy the bacilli that they harbour, along with 
effector T-cells, rendering them capable of killing these 
infected cells. Therefore, T-cell activation is a crucial 
step in leprosy immunity (Murray et al. 2007). The ac-
tivation of T-cells by cognate antigens to proliferate and 
release cytokines requires a two-step signalling process. 
The first signal is produced by the interaction between 
the T-cell receptor and the antigen-major histocompat-
ibility complex provided by the antigen-presenting cell 
and the second signal is mediated through the interac-
tion of costimulatory molecules present on the surfaces 
of the antigen presenting cells (APCs) with their ligands 
on the T-cells (Mueller et al. 1989). The latter is crucial 
for driving the balance between the induction of toler-
ance or anergy and productive T-cell effector and helper 
immune responses. CD80 and CD86 are molecules ex-
pressed by APCs that play a major role in the outcome of 
T-cell activation. Although structurally and functionally 
similar (Bhatia et al. 2006), they exhibit different immu-
nological properties leading to distinct T-cell functional 
outcomes. CD86 has a higher relative affinity for CD28, 
while CD80 has higher affinity for CD152 (Collins et al. 
2002). CD28 is involved in productive T-cell activation, 
signalling for cellular proliferation, interleukin (IL)-2 se-
cretion and cell survival through enhanced Bcl-2 expres-
sion (Bour-Jordan et al. 2011), while CD152 halts T-cell 
activation, favours apoptosis and induces either anergy 
or tolerance (Fife & Bluestone 2008). Moreover, while 
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CD86 and CD28 are constitutively expressed by APC 
and T-cells, respectively, CD80 and CD152 are expressed 
only following 24-48 h of activation of the APC and T-
cell (Lenschow et al. 1996, Bour-Jordan et al. 2011). A 
model of T-cell costimulation has thus been proposed 
in which the distinct structures and binding properties 
of CD86 and CD80 significantly enhance the activating 
and inhibitory functions of CD28 and CD152, respec-
tively (Collins et al. 2002). This seems to be relevant to 
the regulation of the immune responses in several clini-
cal conditions. For example, the increased expression of 
CD86 by monocytes was shown to play a key role in the 
exacerbated inflammatory response of multiple sclerosis 
(Filion et al. 2003); conversely, the defective expression 
of CD86 on monocytes was shown to be crucial in urae-
mia-associated immunodeficiency (Girndt et al. 2001). 
However, other costimulatory molecules have been 
described that influence the subsequent adaptive im-
mune responses, such as programmed death-1 (PD-1) 
and inducible costimulatory protein (ICOS) (Green-
wald et al. 2005). These molecules have been shown 
to play major roles in triggering autoimmunity or pe-
ripheral tolerance and directing the protective immune 
response to pathogens or facilitating the persistence of 
the parasite leading to chronic immune activation (Zhu 
et al. 2011, Bour-Jordan et al. 2011). 
This study aimed to verify the influence of costim-
ulatory molecules on the immune response of subjects 
along the leprosy spectrum. The expression levels of the 
costimulatory molecules CD80, CD86, CD28, CD152, 
PD-1 and ICOS were evaluated in in vitro-stimulated 
peripheral blood mononuclear cells (PBMCs) from 
both lepromatous and tuberculoid patients and healthy 
exposed individuals.
PATienTS, MATeRiALS AnD MeThoDS
Patients and healthy contacts - A total of 28 con-
secutive, newly diagnosed leprosy patients admitted to 
our service were analysed. All patients were studied be-
fore the start of the specific therapy; they were all human 
immunodeficiency virus-negative and had no other in-
fectious comorbidities. Some of the patients had partici-
pated in a previous study (Palermo et al. 2012). Fourteen 
had tuberculoid leprosy (age range 43 ± 5 years, 4 female 
and 10 male subjects), 11 of whom presented with the BT 
and three of whom presented TT. The other 14 patients 
had LL (age range 38 ± 4 years, 6 female and 8 male 
subjects); of these patients, 10 had BL and four presented 
polar LL. A control group composed of 10 healthy M. 
leprae-exposed individuals (contacts, age range 32 ± 4 
years) was selected from among persons living in close 
contact with the LL patients. Exposure was defined 
by a positive response in the lymphoproliferation as-
say with M. leprae antigen, as described below (Table). 
The study was approved by the Ethical Committee of 
the Clinics Hospital, University of São Paulo Medical 
School (protocol 0955/08). Informed consent was ob-
tained from all participants. 
PBMC isolation and cultures - PBMCs were cultured 
as previously described (Cacere et al. 2008). Briefly, PB-
MCs were isolated from heparinised peripheral blood 
by a density gradient and then resuspended in RPMI 
medium supplemented with gentamicin (40 µg/mL) and 
10% human AB serum (Sigma-Aldrich, St. Louis, MO, 
USA). PBMCs (2.5 x 105/well) were cultivated at 37ºC 
and 5% CO2 in the presence of medium only, a cell wall 
preparation from M. leprae (MLCwA)(10 µg/mL) or, as 
a positive control, phytohaemagglutinin (PHA) (5 µg/
mL) (Sigma, Saint Louis, MO, USA). For the lymphop-
roliferation assays, cells were incubated for three days 
(PHA) or six days (MLCwA) and then pulsed for an 
additional 18 h with 1.0 µCi/well [3H]-thymidine (Ra-
diochemical Centre, Amersham, UK) before harvest-
ing. Cell-bound radioactivity was measured using a 
β-counter (Perkin-Elmer, Boston, MA, USA). In some 
experiments, the following blocking monoclonal anti-
bodies were added to the cultures, at 10 μg/mL, from 
the start of the culture (day 0), as described elsewhere 
(Cacere et al. 2008): anti-CD152 (IgG2a, clone BI3) (BD 
Pharmingen, San Diego, CA, USA), anti-CD80 (IgG1,6 
clone 2D10.4) (eBioscience, San Diego, CA, USA) and 
anti-CD86 (IgG2b, clone IT2.2) (eBioscience).
The expression of costimulatory molecules by mono-
cytes and T-cells - For T-cell staining, PBMCs, which 
were isolated as described above from both the con-
tacts and the leprosy patients, were cultured in 24-well 
plates for four days and the cells were then carefully 
collected. Day 4 was considered to be optimal for the 
expression of CD152 and the B7 family of molecules 
on T-cells according to preliminary time-course ex-
periments and previous reports (Cacere et al. 2008). The 
cells were washed twice with cold phosphate buffered 
saline (PBS) and then re-suspended at 1 x 106 cells/mL in 
PBS/bovine serum albumin (BSA) 1% buffer. Aliquots 
containing 2.5 x 105 cells were distributed to cytometer 
tubes and the Fc receptors were blocked by incubation 
for 20 min with human immunoglobulin (50 mg/mL) 
(Baxter Biosciences, Vienna, Austria). After washing 
with PBS-BSA 1%, 10 µL of the following antibodies 
was added: anti-CD3 (tri-colour, Caltag) and anti-CD28 
(PE, Caltag), anti-CD152 (Cy-chrome, Pharmingen), 
anti-PD-1 (FITC, eBioscience), anti-ICOS (PE, eBio-
science), anti-CD80 (FITC, Caltag) or anti-CD86 (PE, 
Caltag). To analyse the expression of CD86 and CD80 on 
peripheral blood monocytes, CD14+ cells were isolated 
from the entire PBMC population by positive selection 
with anti-CD14-conjugated beads (EasySep, StemCell 
Technologies). The purity of the population was always 
≥ 98%. The purified CD14+ population was allowed to 
rest in 24-well plates for 48 h at 37ºC and 5% CO2, a 
step that was necessary for the cells to return to a rest-
ing state after the column passage. After the 24 h resting 
period, MLCwA or Candida Metabolic Antigen (Sanofi-
Pasteur, Paris, France) (5 µg/mL), a control non-related 
antigen, was added and the incubation was continued for 
4 h. Monocytes were carefully collected from the wells 
through several washes with cold RPMI using a 1 mL 
pipette and the cells were washed again with PBS/BSA 
1%, resuspended in PBS/BSA 1% buffer at 106 cells/mL 
and stained with 10 µL of the following antibodies: anti-
CD14 (tri-colour, Caltag, Burlingame, CA, USA) plus 
anti-CD80 (FITC, Caltag) or anti-CD86 (PE, Caltag). For 
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both T-cell and monocyte staining, the tubes containing 
the labelled cells were gently vortexed and incubated in 
the dark for 30 min at room temperature, resuspended 
in 500 µL of PBS/BSA 1% buffer, washed in PBS to re-
move unbound antibody and finally suspended in PBS-
azide. In each experiment, one tube remained without 
mAb addition as an autofluorescence control. In addi-
tion, each protocol was set up with colour compensation 
controls. Cells were immediately acquired and analysed 
on a Coulter flow cytometer using the software System II 
(Coulter Epics XL-MCL, Hialeah, FL, USA). The results 
were expressed as percentages of costimulatory mole-
cule-expressing cells and mean fluorescence intensities 
(MFIs) per at least 10,000 CD3+ or CD14+ gated cells.
Statistical analysis - The comparison of data from 
among the three groups was performed using one-way 
analysis of variance and the Newman-Keuls multiple 
comparison test. The differences were considered sig-
nificant when p < 0.05. GraphPad Prism 5.0 software 
was used (Graph Pad Software Inc San Diego, CA).
ReSuLTS
Proliferative responses - The Table shows that the 
PBMCs of patients with the lepromatous form of leprosy 
were anergic to MLCwA, while positive responses were 
observed for the tuberculoid patients and contacts. The 
responses to PHA were not significantly different among 
the three groups. 
CD86 and CD80 expression by CD14+ cells - Signifi-
cantly fewer monocytes (CD14+ cells) from lepromatous 
patients (~50%) expressed the costimulatory molecule 
CD86 compared with tuberculoid patients and contacts 
(~80%) after 4 h of culture in the presence of medium 
only or MLCwA (Fig. 1A). There were no significant dif-
ferences in CD86 expression when the monocytes were 
challenged with a control antigen from Candida spp. The 
analysis of the CD86 MFI data revealed a similar trend; 
monocytes from lepromatous patients expressed the mol-
ecule at lower densities in the presence of medium only 
or MLCwA (Fig. 1B). In contrast, CD80 was poorly ex-
pressed by monocytes (< 10%) that were either unchal-
lenged or challenged with the antigens, with no significant 
differences among the three groups (data not shown). 
The expression of costimulatory molecules by CD3+ 
cells - CD28 was similarly expressed by high percent-
ages of CD3+ cells from all three groups of patients (Fig. 
2C); however, the MFI differed among the groups (Fig. 
2D). CD3+ cells from unstimulated and MLCwA-stimu-
lated cultures of PBMCs from both lepromatous patients 
TABLE
Lymphocyte proliferative responses 
Subjects
Medium
(cpm)
MLCwA
(cpm)
Phytohaemagglutinin 
(cpm)
Contacts
(n = 9) 521 ± 66 6.216 ± 621 27.351 ± 7.457
Tuberculoid leprosy
(n = 11) 744 ± 266 6.734 ± 1771 28.813 ± 9.331
Lepromatous leprosy
(n = 13) 509 ± 138 1.120 ± 149
a 34.379 ± 7.606
a: p < 0.01 vs. contacts and tuberculoid leprosy (one-way analysis of variance with Newmans-Keuls post-test); cpm: counts 
per minute; MLCwA: Mycobacterium leprae antigen.
Fig. 1: expression of CD86 on monocytes (CD14+ cells) from tubercu-
loid (n = 7) and lepromatous (n = 10-11) leprosy patients and healthy 
exposed contacts (n = 6) challenged with Candida Metabolic Anti-
gen (CMA) or a Mycobacterium leprae antigen (MLCwA) or unchal-
lenged (medium). Results are presented as mean ± standard error of 
the means of the percentage of expressing cells (A) and mean fluores-
cence intensity (MFI) of the molecule (B). *: p < 0.05; **: p < 0.01. 
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and contacts expressed CD28 at lower intensities than 
those from tuberculoid patients. The CD28 MFI was 
comparable in CD3+ cells stimulated with PHA, which 
was used as a positive control.
As observed above for CD14+ cells, CD80 expression 
in unstimulated and MLCwA-stimulated CD3+ cells was 
poor (< 10%) in all three groups (data not shown). CD86 
was expressed by higher numbers of CD3+ cells, but with 
no significant differences among the three groups (Fig. 
2A). However, the MFI of CD86 in lepromatous patients’ 
CD3+ cells was significantly reduced compared with the 
MFIs from tuberculoid patients and contacts in all three 
experimental conditions (Fig. 2B). 
The expression of the negative signalling molecules 
CD152 and PD-1 also differed among groups (Fig. 3). 
Higher proportions of unstimulated and PHA and ML-
CwA-stimulated CD3+ cells from tuberculoid patients 
expressed CD152 with a higher MFI than the same cells 
from lepromatous patients and contacts (Fig. 3A, B). 
With regard to PD-1, significantly higher proportions of 
CD3+ cells from both lepromatous and tuberculoid pa-
tients expressed this molecule compared with contacts 
either when cultured in medium only or in the presence 
of MLCwA (Fig. 3C). With PHA, the patients’ CD3+ cells 
also expressed higher levels than the cells from contacts, 
although the differences did not reach statistical signifi-
cance. PD-1 MFI did not differ among groups (Fig. 3D).
ICOS expression was low in CD3+ cells and was not 
different among groups in any of the experimental con-
ditions studied (data not shown).
Blocking experiments - We tested the effect of anti-
CD152, anti-CD86 and anti-CD80 blocking antibodies 
in PBMC cultures from six donors, three tuberculoid pa-
tients and three contacts who had positive proliferative 
responses to MLCwA. As shown in Fig. 4, CD86 block-
ade reduced the proliferative response to MLCwA to less 
than 50% of the control cultures while CD80 blockade 
had no effect; CD152 blockade slightly but significantly 
increased the response. 
DiSCuSSion
Our data demonstrate that CD86, but not CD80, seems 
to play a critical role in the presentation of leprosy anti-
gens by monocytes. The blockade of CD86 signalling, but 
not the blockade of CD80 signalling, with a neutralising 
monoclonal antibody resulted in significant inhibition of 
the proliferative response to M. leprae antigens. Accord-
ingly, CD86, but not CD80, was differentially expressed 
among contacts and patients; the former was highly ex-
pressed by monocytes from both healthy individuals ex-
posed to M. leprae (contacts) and patients at the tubercu-
loid pole of leprosy, while the latter was poorly expressed 
by both patients and contacts. In contrast, monocytes 
from patients at the LL pole exhibited a striking deficien-
cy in the expression of CD86. This deficiency may help 
to explain the well-described differences in the T-cell 
responses between lepromatous and tuberculoid patients 
(Yamamura et al. 1991). In fact, unlike the tuberculoid 
patients, our lepromatous patients were unable to mount 
strong cellular immune responses against M. leprae anti-
gens, as demonstrated in vivo by the poor granulomatous 
Fig. 2: expression of CD86 and CD28 on T-lymphocytes (CD3+ cells) 
from tuberculoid (n = 10) and lepromatous (n = 12-14) leprosy patients 
and healthy exposed contacts (n = 10) stimulated with phytohemaglu-
tinnin (PHA) or a Mycobacterium leprae antigen (MLCwA) or unstim-
ulated (medium). Results are presented as mean ± standard error of the 
means of the percentage of expressing cells (A, C) and mean fluores-
cence intensity (MFI) of the molecule (B, D). *: p < 0.05; **: p < 0.01. 
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inflammatory response and high bacillary load reported 
in a previous study (Palermo et al. 2012) and as observed 
in vitro in this study by the reduced antigen-specific pro-
liferative responses. These findings may be explained by 
the reduced expression of CD86 during the early stage 
of recognition and presentation of M. leprae-derived an-
tigens in lepromatous lesions, which interferes with the 
formation of the immune synapse that is required to ef-
ficiently activate the T-cells and generate effector T-cells 
(Lanzavecchia & Sallusto 2000). 
Previous data on CD80 and CD86 in leprosy are 
scarce and controversial, suggesting either a role for 
CD80 in the anergy of lepromatous patients or enhanced 
CD80 expression as a predictor of reaction states (Agre-
wala et al. 1998, Schlienger et al. 1998, Santos et al. 
2007). Differences in the methods and the types of cells 
analysed and in the nature of the antigen used may ac-
count for the different results.
Several mechanisms may be put forward to explain 
the deficient CD86 expression by LL patients. T-regs have 
been shown to down-modulate the expression of CD80 
and CD86 on APCs (Cederbom et al. 2000), likely through 
direct cell-to-cell interactions. We have previously dem-
onstrated that these patients have increased numbers of 
T-regs, both in situ and in vitro (Palermo et al. 2012). IL-
10 has been shown to down-modulate CD86 expression 
on monocytes (Creery et al. 1996). In LL, the monocytes 
are exposed to highly IL-10-enriched microenvironments 
because in this form of leprosy, IL-10 expression is sig-
nificantly enhanced in both in situ and in vitro-stimulated 
PBMCs; in contrast, in tuberculoid leprosy, the IL-10 lev-
els are low (Moubasher et al. 1998, Palermo et al. 2012). 
Alternatively, the process of monocyte invasion by M. 
leprae by itself could down-modulate CD86 expression 
on the host cell, as has been demonstrated with Mycobac-
terium tuberculosis infection (Castaño et al. 2011).
Differential costimulatory molecule expression by 
T-cells was also verified among our lepromatous and 
tuberculoid patients and contacts. Molecules that either 
signal for (CD86 and CD28) or reduce (CD152 and PD-1) 
T-cell activation were evaluated. Probably as a con- 
Fig. 3: expression of CD152 and programmed death-1 (PD-1) on T-
lymphocytes (CD3+ cells) from tuberculoid (n = 9-14) and leproma-
tous (n = 10-11) leprosy patients and healthy exposed contacts (n = 
8) stimulated with phytohemaglutinnin (PHA) or a Mycobacterium 
leprae antigen (MLCwA) or unstimulated (medium). Results are pre-
sented as mean ± standard error of the means of the percentage of 
expressing cells (A, C) and mean fluorescence intensity (MFI) of the 
molecule (B, D). *: p< 0.05; **: p < 0.01. 
Fig. 4: effect of anti-CD80, anti-CD86 and anti-CD152 blocking 
monoclonal antibodies on the lymphocyte proliferative response to 
Mycobacterium leprae antigen (MLCwA) of six subjects responders 
(3 contacts and 3 tuberculoid patients) to MLCwA (●). No effect was 
seen in unstimulated cells (○). *: p < 0.05 vs. nil.
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sequence of defective APC function, T-cells from lep-
romatous patients were driven to an anergic state and 
exhibited reduced expression of both CD86 and CD28, 
especially when compared with tuberculoid patients. 
The latter exhibited the highest levels of expression, 
especially regarding CD28 expression, which was even 
significantly higher than even that of the contacts. This 
would indicate an on-going exacerbated T-cell response. 
However, T-cells from these patients also exhibited en-
hanced CD152 expression, possibly preventing an un-
controlled immune reaction. The net result would be an 
effective immune response capable of limiting bacillary 
multiplication and the dissemination of lesions without 
causing immunopathology. The expression of CD152 
by the T-cells from contacts was significantly lower 
than that from tuberculoid patients, which suggests that 
distinct immune regulatory mechanisms take place in 
tuberculoid patients’ and contacts’ M. leprae-specific 
responses. Consistent with the fact that CD152 expres-
sion is cell-activation dependent, when resting-state 
molecules found in intracellular reservoirs are rapidly 
mobilised to the cell surface (Schneider et al. 2006), T-
cells from lepromatous patients exhibited low levels of 
expression of this molecule. Moreover, corroborating 
with its inhibitory function in leprosy, the blockade of 
CD152 resulted in a slight but significant enhancement 
of the M. leprae-specific proliferative responses.
Interestingly, the pattern of expression of the inhibi-
tory molecule PD-1 differed from that of CD152. In fact, 
it has been suggested that PD-1 and CD152 play comple-
mentary and non-overlapping roles in peripheral T-cell 
hypo-responsiveness (Fife & Bluestone 2008). CD152 
may predominantly control the T-cell response at the 
induction phase, while PD-1 may be responsible for the 
maintenance of the tolerant or anergic state. PD-1 intrin-
sically inhibits the function of effector T-cells (Fife et 
al. 2006) and it may also act by affecting the stability of 
their ligation with DCs (Fife et al. 2009). A significantly 
higher number of T-cells expressed PD-1 in tuberculoid 
and lepromatous patients than in contacts, thus serving 
as a marker of disease. In fact, PD-1 is highly expressed 
in situations of high and constant antigen exposure, such 
as chronic viral infections or malignancy (Barber et al. 
2006, Zhu et al. 2011). Chronic exposure to mycobacte-
rial antigens is indeed a feature of leprosy patients due to 
the protracted evolution of the disease. 
Finally, the T-cell expression levels of CD80 and 
ICOS were also examined and indicated low levels of 
expression (data not shown), likely suggesting that they 
play minor roles in the regulation of the immune re-
sponse in leprosy.
Based on our findings, a model can be built that 
proposes that, in LL, the defective APC function due 
to reduced CD86 expression by these cells results in 
an abnormal T-cell activation characterised by reduced 
antigen-specific proliferative responses and the deficient 
expression of CD28 and CD86 on T-cells. CD152 is not 
required for the induction of this anergic state. However, 
the chronic exposure to M. leprae antigens enhances 
PD-1 expression, which reinforces the state of tolerance 
against the bacillus. Consequently, patients develop a dis-
seminated multi-bacillary disease. In tuberculoid lepro-
sy, proficient APC function exists, positive proliferative 
responses are detected and high expression levels of posi-
tive signalling molecules on T-cells (CD28 and CD86) are 
detected. However, these positive signalling molecules 
need to be counter-regulated by the enhanced expression 
of inhibitory molecules (CD152 and PD-1), thus allow-
ing a balanced effective immune response to be reached, 
i.e., control of the parasite burden without causing im-
mune pathology. In contacts, there is no deficiency in 
the antigen-presenting process and a balanced immune 
response “naturally” develops because enhanced expres-
sion of negative signalling molecules is not required. A 
better understanding of the immune regulation of the 
host immune response in leprosy may allow for immune 
interventions that would impact the prognosis of this still 
poorly controlled infectious disease.
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